+39 02 610346.1 - info@newron.com

Press Releases

Filter by year
  • november302018

    Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease


  • october312018

    Newron Pharmaceuticals hosts its 2018 R&D Day in New York City

  • october302018

    Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m


  • october232018

    Meiji Seika and Eisai announce submission of manufacturing and marketing approval application in Japan for safinamide in Parkinson’s disease

  • october152018

    Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York


  • october82018

    Newron Dedicates Efforts to Research and Advocacy During Rett Awareness Month in October


  • september252018

    Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

  • september132018

    Newron reports half-year 2018 results


  • september122018

    Newron Pharmaceuticals will host its 2018 R&D Day on October 31 in New York City


  • august12018

    Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

  • june132018

    Newron provides update on STARS clinical study with sarizotan for the treatment of Rett syndrome


  • may292018

    Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

  • may152018

    Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 2018

  • march272018

    Shareholders accepted all motions at the AGM 2018


  • march12018

    Newron announces 2017 financial results and provides outlook for 2018


  • february132018

    Newron Supports Global Rare Disease Day® 2018 and Rett Syndrome Studies


  • february82018

    Change in the Board of Directors


  • february12018

    Primary endpoint met in phase II/III clinical study of investigational Parkinson’s disease treatment safinamide in Japan